MaxCyte IPO Presentation Deck

The EXPERT™ Platform Enabling Non-viral Cell Engineering • Launched in 2019 based on MaxCyte's proprietary Flow Electroporation® technology that has been optimized over 20+ years • Leverages the reversible permeability of the cell membrane in response to an electric charge • Universally delivers molecules, such as nucleic acids and proteins, to cells • Agnostic to cell type, approach (auto/allo) and/or gene manipulation technology • Enables customers to use a single platform from concept through to the clinic in a GMP environment • Supported by a robust intellectual property portfolio (50+ patents in US and foreign jurisdictions and 75+ patents pending) July 2021 ATX EXPERT Instrument Portfolio Small to mid-scale RUO STx Full scale RUO CONFIDENTIAL GTX High Performance >90% transfection efficiencies (depending on cell type and molecule) >90% cell viabilities Computer-controlled system for reproducible results Scalability - ability to transfect: 75,000 to 7 million cells in seconds Full scale GMP Flexibility • Single, fully-defined, animal component-free electroporation buffer for all cell types Pre-loaded library of validated, cell-specific products Up to 20 billion cells in less than 30 minutes And up to 200 billion cells in less than 30 minutes with the high scale VLX High Quality Sterile, single-use processing assemblies (PAS) - "disposables" Closed, cGMP-compliant, ISO-certified, and CE marked instruments Supported by US FDA Master File and global equivalents 11

View entire presentation